Dri Biosciences Corp
DRI Biosciences Corporation is developing proprietary and game-changing therapeutics to improve conditions of Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD). FXS represents the most common form of inherited intellectual disability and is a frequent monogenic cause of autism. In the U.S. and Europe, there are more than cases of FXS. Meanwhile, the total autistic incidence is approaching 2 million worldwide. The predicted therapeutic market is estimated at $5.5 billion by 2018, but there are no medications that effectively treat or improve these neurodevelopmental conditions.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
1 to 10
headcount range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Dri Biosciences Corp
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Dri Biosciences Corp
1 distinct titles indexed · top 1 shown.
- 1chief executive officer
Sign up to unlock all 1 contacts at Dri Biosciences Corp
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Dri Biosciences Corp
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.